ImmuPharma

ImmuPharma EBIT

The EBIT of ImmuPharma (IMM.L) as of Nov 22, 2026 is -2.54 M GBP. In the previous year, EBIT was -2.68 M GBP — a change of -4.96% (higher).

EBIT

-2.54 MGBP

YoY

-4.96%

Last updated:

In 2025, ImmuPharma's EBIT was -2.54 M GBP, a -4.96% increase from the -2.68 M GBP EBIT recorded in the previous year.

The ImmuPharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-3.06 M GBP
Jan 1, 2024
-2.68 M GBP
Jan 1, 2025
-2.54 M GBP
Jan 1, 2026 (e)
-15.50 M GBP
Jan 1, 2027 (e)
-20.89 M GBP
Jan 1, 2028 (e)
-14.22 M GBP
Jan 1, 2029 (e)
-13.73 M GBP
Jan 1, 2030 (e)
-14.22 M GBP
The ImmuPharma EBIT history
YEAREBITYoY
est-14.22 MGBP+3.57%
est-13.73 MGBP-3.45%
est-14.22 MGBP-31.93%
est-20.89 MGBP+34.82%
est-15.50 MGBP+509.48%
-2.54 MGBP-4.96%
-2.68 MGBP-12.66%
-3.06 MGBP+1.12%
-3.03 MGBP-54.02%
-6.59 MGBP+17.86%
-5.59 MGBP-11.03%
-6.28 MGBP-22.25%
-8.08 MGBP+11.69%
-7.23 MGBP+9.79%
-6.59 MGBP+44.40%
-4.56 MGBP+33.23%
-3.43 MGBP-18.99%
-4.23 MGBP+1.27%
-4.18 MGBP+8.84%
-3.84 MGBP-8.23%
-4.18 MGBP-140.59%
10.30 MGBP-325.11%
-4.58 MGBP+29.68%
-3.53 MGBP+129.99%
-1.53 MGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuPharma Revenue

ImmuPharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 GBP
-3.06 M GBP
-2.92 M GBP
Jan 1, 2024
0.00 GBP
-2.68 M GBP
-2.48 M GBP
Jan 1, 2025
0.00 GBP
-2.54 M GBP
-1.81 M GBP
Jan 1, 2026 (e)
74,216.00 GBP
-15.50 M GBP
-13.16 M GBP
Jan 1, 2027 (e)
74,216.00 GBP
-20.89 M GBP
-17.74 M GBP
Jan 1, 2028 (e)
74,216.00 GBP
-14.22 M GBP
-12.08 M GBP
Jan 1, 2029 (e)
74,216.00 GBP
-13.73 M GBP
-11.66 M GBP
Jan 1, 2030 (e)
74,216.00 GBP
-14.22 M GBP
-12.08 M GBP

ImmuPharma Margins

ImmuPharma stock margins

The ImmuPharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImmuPharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImmuPharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
-20,881.35 %
-17,731.24 %
Jan 1, 2027 (e)
100.00 %
-28,152.65 %
-23,903.51 %
Jan 1, 2028 (e)
100.00 %
-19,162.68 %
-16,272.34 %
Jan 1, 2029 (e)
100.00 %
-18,501.65 %
-15,711.23 %
Jan 1, 2030 (e)
100.00 %
-19,162.68 %
-16,272.34 %

ImmuPharma Stock analysis

What does ImmuPharma do? ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing ImmuPharma's EBIT

ImmuPharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ImmuPharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ImmuPharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ImmuPharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ImmuPharma stock

EBIT of ImmuPharma is -2.54 M GBP in 2025.

EBIT of ImmuPharma changed from -2.68 M GBP to -2.54 M GBP, representing a -4.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT ImmuPharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's ImmuPharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ImmuPharma

All Key Metrics — ImmuPharma